385 related articles for article (PubMed ID: 28610444)
21. The importance of FLT3 mutational analysis in acute myeloid leukemia.
Patnaik MM
Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
[TBL] [Abstract][Full Text] [Related]
22. Midostaurin + Chemo Ups AML Survival.
Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D
Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
[TBL] [Abstract][Full Text] [Related]
24. Updated safety of midostaurin plus chemotherapy in newly diagnosed
Roboz GJ; Strickland SA; Litzow MR; Dalovisio A; Perl AE; Bonifacio G; Haines K; Barbera A; Purkayastha D; Sweet K
Leuk Lymphoma; 2020 Dec; 61(13):3146-3153. PubMed ID: 32812818
[TBL] [Abstract][Full Text] [Related]
25. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
[TBL] [Abstract][Full Text] [Related]
26. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
27. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
28. Midostaurin approved for FLT3-mutated AML.
Levis M
Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
[TBL] [Abstract][Full Text] [Related]
29. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Stone RM; Manley PW; Larson RA; Capdeville R
Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
[TBL] [Abstract][Full Text] [Related]
30. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Stone RM; Fischer T; Paquette R; Schiller G; Schiffer CA; Ehninger G; Cortes J; Kantarjian HM; DeAngelo DJ; Huntsman-Labed A; Dutreix C; del Corral A; Giles F
Leukemia; 2012 Sep; 26(9):2061-8. PubMed ID: 22627678
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
[TBL] [Abstract][Full Text] [Related]
32. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
33. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
34. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N; Venugopal S; Ravandi F
Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
36. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
[TBL] [Abstract][Full Text] [Related]
37. Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
Schlafer D
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365750
[No Abstract] [Full Text] [Related]
38. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Wang ES
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
[TBL] [Abstract][Full Text] [Related]
39. Availability of FLT3 inhibitors: how do we use them?
Perl AE
Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
[TBL] [Abstract][Full Text] [Related]
40. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Galinsky I; Coleman M; Fechter L
Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
